{"organizations": [], "uuid": "231d214348fa574da364715da08696b5f452e882", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-charles-river-laboratories-to-buy/brief-charles-river-laboratories-to-buy-mpi-research-for-about-800-mln-idUSASB0C5DE", "country": "US", "domain_rank": 408, "title": "Charles River Laboratories To Buy MPI Research For About $800 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-13T20:30:00.000+02:00", "replies_count": 0, "uuid": "231d214348fa574da364715da08696b5f452e882"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-charles-river-laboratories-to-buy/brief-charles-river-laboratories-to-buy-mpi-research-for-about-800-mln-idUSASB0C5DE", "ord_in_thread": 0, "title": "Charles River Laboratories To Buy MPI Research For About $800 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - charles river laboratories international inc", "sentiment": "neutral"}, {"name": "mpi", "sentiment": "none"}, {"name": "uire mpi", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Charles River Laboratories International Inc:\n* CHARLES RIVER LABORATORIES TO ACQUIRE MPI RESEARCH * CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL FOR APPROXIMATELY $800 MILLION\n* CHARLES RIVER LABORATORIES - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EPS BY APPROXIMATELY $0.25 IN 2018 AND APPROXIMATELY $0.60 IN 2019​\n* CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍FOR 2017, MPI IS EXPECTED TO GENERATE ANNUAL REVENUE OF APPROXIMATELY $240 MILLION​\n* CHARLES RIVER LABORATORIES INTERNATIONAL - ‍EXPECTS TO GENERATE OPERATIONAL SYNERGIES AS RESULT OF DEAL, WITH BENEFITS TOTALING $13 TO $16 MILLION BY END OF 2019​\n* CHARLES RIVER LABORATORIES - DEAL EXPECTED TO ADD $170 TO $190 MILLION TO CHARLES RIVER‘S 2018 CONSOLIDATED REVENUE BASED ON ANTICIPATED TIMING OF CLOSE​\n* CHARLES RIVER LABORATORIES INTERNATIONAL - ‍ACQUISITION & ASSOCIATED FEES ARE EXPECTED TO BE FINANCED THROUGH AN EXPANSION OF CO‘S CREDIT FACILITY & CASH​\n* CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍COMPANY IS EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE ACQUISITION​\n* CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ACQUISITION IS EXPECTED TO ADD $260 TO $280 MILLION TO 2019 CONSOLIDATED REVENUE​\n* CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL,ASSOCIATED FEES EXPECTED TO BE FINANCED THROUGH EXPANSION OF CHARLES RIVER‘S CREDIT FACILITY, CASH​\n* CHARLES RIVER LABORATORIES - ‍EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE DEAL AND FOR GENERAL CORPORATE PURPOSES​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T20:30:00.000+02:00", "crawled": "2018-02-14T12:23:03.000+02:00", "highlightTitle": ""}